去纤苷（去纤维钠）的说明书

For patients who have undergone hematopoietic stem cell transplantation (HSCT), the emergence of complications is likely to affect their life and health. Hepatic veno-occlusive disease (HVOD) is one of its serious complications. The mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide is a single-stranded oligonucleotide mixture with anti-thrombotic and fibrinolytic effects. It is currently recognized as the most promising new drug for the treatment of HVOD after HSCT.

Defibrinoside (Defibrinated Sodium) is not currently on the market in my country, and many patients do not know how to use it. The following is the instruction manual of Defibrinated Sodium (Defibrinated Sodium) compiled by Medical Companion Travel. I hope it will be helpful to you.

Drug name: Defibrinoside

Product name: Defitelio

Other names: Sodium defibrotide, defibrotide

Manufacturer: Jazz Pharmaceuticals plc

Indications: Defibrotide is indicated for the treatment of adults and children with hepatic veno-occlusive disease (HVOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT).

Dosage: Defibrotide is suitable for both children and adults. The recommended dose is 6.25 mg/kg given as a 2-hour intravenous infusion every 6 hours. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol.

The minimum duration of treatment with defibrotide (sodium defibrotide) is 21 days. If the signs and symptoms of hepatic VOD do not resolve after 21 days, use may be continued until the condition resolves, or for a maximum of 60 days.

Preparation for injection:

1. Defibrotide must be diluted before infusion.

2. Administer defibrotide by constant intravenous infusion over a 2-hour period.

3. In order to ensure patient medication safety, before starting defibrotide treatment, it must be ensured that the patient has not experienced clinically significant bleeding and is hemodynamically stable on no more than one vasopressin.

4. Administer the diluted defibrotide solution using an infusion set equipped with a 0.2 micron in-line filter. Flush the intravenous administration line (peripheral or central) with 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, before and immediately after administration.

5. Do not co-administer defibrotide and other intravenous drugs in the same intravenous line at the same time.

Contraindications: Defibrotide is contraindicated in concurrent administration with systemic anticoagulants or fibrinolytic therapy. Known hypersensitivity to defibrotide or to any excipient is contraindicated.

The above is a brief description of the drug Defibrotide (Defibrotide Sodium). Patients must strictly follow the doctor's instructions and use the drug correctly during treatment.